{"id":724946,"date":"2024-12-19T09:24:01","date_gmt":"2024-12-19T09:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=724946"},"modified":"2024-12-19T09:24:01","modified_gmt":"2024-12-19T09:24:01","slug":"cryopyrinassociated-periodic-syndrome-pipeline-status-2024-clinical-trials-overview-and-key-companies-involved-by-delveinsight-zydus-cadila-novartis-inflazome-roche-aclaris-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cryopyrinassociated-periodic-syndrome-pipeline-status-2024-clinical-trials-overview-and-key-companies-involved-by-delveinsight-zydus-cadila-novartis-inflazome-roche-aclaris-therapeutics_724946.html","title":{"rendered":"Cryopyrin-Associated Periodic Syndrome Pipeline Status 2024: Clinical Trials Overview and Key Companies involved by DelveInsight | Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1734550403.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cryopyrin-Associated Periodic Syndrome Pipeline Status 2024: Clinical Trials Overview and Key Companies involved by DelveInsight | Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1734550403.png\" alt=\"Cryopyrin-Associated Periodic Syndrome Pipeline Status 2024: Clinical Trials Overview and Key Companies involved by DelveInsight | Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Cryopyrin-Associated Periodic Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Cryopyrin-Associated Periodic Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Cryopyrin-Associated Periodic Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Cryopyrin-Associated Periodic Syndrome Pipeline Insight, 2024<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cryopyrin-Associated Periodic Syndrome Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Cryopyrin-Associated Periodic Syndrome Pipeline Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Companies across the globe are diligently working toward developing novel Cryopyrin-Associated Periodic Syndrome treatment therapies with a considerable amount of success over the years.&nbsp;<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome companies working in the treatment market are <strong>NLRP3 Secarna Pharmaceuticals, Novartis Pharmaceutical, Zydus Lifesciences Ltd., Novartis Pharmaceuticals, Aclaris Therapeutics, Inflazome, and others<\/strong>, are developing therapies for the Cryopyrin-Associated Periodic Syndrome treatment&nbsp;<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Emerging Cryopyrin-Associated Periodic Syndrome therapies in the different phases of clinical trials are- <strong>Research Program, DFV890, ZYIL1, DFV890, Zunsemetinib, IZD334, and others<\/strong> are expected to have a significant impact on the Cryopyrin-Associated Periodic Syndrome market in the coming years.&nbsp;<\/p>\n<\/li>\n<li>\n<p><strong>In March 2024, Ventyx Biosciences<\/strong> has completed a Phase 2 trial of VTX2735 in patients with cryopyrin-associated periodic syndromes (CAPS), a group of rare autoinflammatory diseases caused by gain-of-function mutations in the NLRP3 gene. The trial enrolled 7 patients with familial cold autoinflammatory syndrome (FCAS), the most common form of CAPS. Treatment with VTX2735 showed significant improvements in disease activity, including an 85% average reduction in the Key Symptom Score during Treatment Period 1.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cryopyrin-Associated Periodic Syndrome Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare, inherited autoinflammatory disorders caused by mutations in the NLRP3 gene, which encodes the cryopyrin protein. This protein plays a key role in regulating inflammation in the body. CAPS includes conditions such as Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal-onset Multisystem Inflammatory Disease (NOMID). These conditions are characterized by recurrent episodes of fever, rash, joint pain, and inflammation, often triggered by environmental factors like cold temperatures. CAPS can lead to long-term damage if untreated. Treatment typically involves medications to control inflammation, such as interleukin-1 (IL-1) inhibitors.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Cryopyrin-Associated Periodic Syndrome Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Cryopyrin-Associated Periodic Syndrome Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Research Program:<\/strong> NLRP3 Secarna Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>DFV890:<\/strong> Novartis Pharmaceutical<\/p>\n<\/li>\n<li>\n<p><strong>ZYIL1:<\/strong> Zydus Lifesciences Ltd.<\/p>\n<\/li>\n<li>\n<p><strong>DFV890:<\/strong> Novartis Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>Zunsemetinib :<\/strong> Aclaris Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>IZD334:<\/strong> Inflazome<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cryopyrin-Associated Periodic Syndrome Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Cryopyrin-Associated Periodic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intra-articular<\/p>\n<\/li>\n<li>\n<p>Intraocular<\/p>\n<\/li>\n<li>\n<p>Intrathecal<\/p>\n<\/li>\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Ophthalmic<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<li>\n<p>Transdermal<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cryopyrin-Associated Periodic Syndrome Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Cryopyrin-Associated Periodic Syndrome Products have been categorized under various Molecule types, such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oligonucleotide<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cryopyrin-Associated Periodic Syndrome Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome Assessment by Product Type<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome By Stage and Product Type<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome Assessment by Route of Administration<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome By Stage and Route of Administration<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome Assessment by Molecule Type<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome by Stage and Molecule Type<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Cryopyrin-Associated Periodic Syndrome Report covers around 4+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<li>\n<p>Route of Administration<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Cryopyrin-Associated Periodic Syndrome product details are provided in the report. Download the Cryopyrin-Associated Periodic Syndrome pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Cryopyrin-Associated Periodic Syndrome therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Cryopyrin-Associated Periodic Syndrome Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Cryopyrin-Associated Periodic Syndrome are &#8211; <em><strong>Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, Mabpharm, Regeneron Pharmaceuticals, and others.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cryopyrin-Associated Periodic Syndrome Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Cryopyrin-Associated Periodic Syndrome pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights about companies that are developing therapies for the treatment of Cryopyrin-Associated Periodic Syndrome with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li>\n<p>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cryopyrin-Associated Periodic Syndrome Treatment.<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Cryopyrin-Associated Periodic Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cryopyrin-Associated Periodic Syndrome market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Cryopyrin-Associated Periodic Syndrome drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cryopyrin-Associated Periodic Syndrome Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Increase in prevalence of Cryopyrin Associated Periodic Syndrome, increase in Research and Development are some of the important factors that are fueling the Cryopyrin-Associated Periodic Syndrome Market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cryopyrin-Associated Periodic Syndrome Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>However, high cost associated with the treatment, lack of effective treatment available and other factors are creating obstacles in the Cryopyrin-Associated Periodic Syndrome Market growth.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Cryopyrin-Associated Periodic Syndrome Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Coverage: Global<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Key Cryopyrin-Associated Periodic Syndrome Companies:<\/strong> NLRP3 Secarna Pharmaceuticals, Novartis Pharmaceutical, Zydus Lifesciences Ltd., Novartis Pharmaceuticals, Aclaris Therapeutics, Inflazome, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Cryopyrin-Associated Periodic Syndrome Therapies:<\/strong> Research Program, DFV890, ZYIL1, DFV890, Zunsemetinib, IZD334, and others<\/p>\n<\/li>\n<li>\n<p><strong>Cryopyrin-Associated Periodic Syndrome Therapeutic Assessment:<\/strong> Cryopyrin-Associated Periodic Syndrome current marketed and Cryopyrin-Associated Periodic Syndrome emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Cryopyrin-Associated Periodic Syndrome Market Dynamics: Cryopyrin-Associated Periodic Syndrome market drivers and Cryopyrin-Associated Periodic Syndrome market barriers&nbsp;<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cryopyrin-associated-periodic-syndrome-caps-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Cryopyrin-Associated Periodic Syndrome Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Cryopyrin-Associated Periodic Syndrome Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Cryopyrin-Associated Periodic Syndrome Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Cryopyrin-Associated Periodic Syndrome Overview<\/p>\n<p style=\"text-align: justify;\">4. Cryopyrin-Associated Periodic Syndrome- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Cryopyrin-Associated Periodic Syndrome Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Cryopyrin-Associated Periodic Syndrome Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Cryopyrin-Associated Periodic Syndrome Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Cryopyrin-Associated Periodic Syndrome Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Cryopyrin-Associated Periodic Syndrome Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Cryopyrin-Associated Periodic Syndrome Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Cryopyrin-Associated Periodic Syndrome Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Cryopyrin-Associated Periodic Syndrome Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Cryopyrin-Associated Periodic Syndrome Key Products<\/p>\n<p style=\"text-align: justify;\">15. Cryopyrin-Associated Periodic Syndrome Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Cryopyrin-Associated Periodic Syndrome Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Cryopyrin-Associated Periodic Syndrome Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Cryopyrin-Associated Periodic Syndrome Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cryopyrinassociated-periodic-syndrome-pipeline-status-2024-clinical-trials-overview-and-key-companies-involved-by-delveinsight-zydus-cadila-novartis-inflazome-roche-aclaris-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cryopyrinassociated-periodic-syndrome-pipeline-status-2024-clinical-trials-overview-and-key-companies-involved-by-delveinsight-zydus-cadila-novartis-inflazome-roche-aclaris-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Cryopyrin-Associated Periodic Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Cryopyrin-Associated Periodic Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cryopyrinassociated-periodic-syndrome-pipeline-status-2024-clinical-trials-overview-and-key-companies-involved-by-delveinsight-zydus-cadila-novartis-inflazome-roche-aclaris-therapeutics_724946.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406],"tags":[],"class_list":["post-724946","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/724946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=724946"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/724946\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=724946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=724946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=724946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}